<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03207620</url>
  </required_header>
  <id_info>
    <org_study_id>IBBAAS</org_study_id>
    <nct_id>NCT03207620</nct_id>
  </id_info>
  <brief_title>Interrelation Between Bronchial Asthma and Smoking</brief_title>
  <official_title>Interrelation Between Bronchial Asthma and Smoking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Smoking occurs frequently in patients with asthma. Recent surveys on smoking prevalence
      report 21-26% current smokers in populations of patients with asthma. Detrimental effects of
      active smoking in asthma include worse asthma control, an impaired response to
      corticosteroids and accelerated lung function decline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mechanisms by which cigarette smoking contributes to disease severity in asthma are
      incompletely understood, but it has been suggested that cigarette smoking may change
      inflammation and airway remodelling in asthma to become more similar to that in COPD (chronic
      obstructive pulmonary disease).

      Any form of tobacco use, especially cigarette smoking, plays an important role in this
      disease. Asthmatic smokers are prone to several negative outcomes. Cigarette smoking by
      itself is associated with airway inflammation and features of airway remodelling including
      increased epithelial proliferation, squamous cell metaplasia, goblet cell hyperplasia, smooth
      muscle hypertrophy, and increases in bronchial glands mass.

      Corticosteroid insensitivity is an important clinical feature of asthma, particularly in
      patients with severe disease and smokers. The mechanisms of corticosteroid insensitivity in
      asthmatic patients are poorly understood.

      One of the major problems in the treatment of smoking asthma patients is the lack of efficacy
      data in this group of patients as smokers have almost always been excluded from studies on
      asthma due to perceived concerns about recruiting patients with COPD. Therefore, there is a
      lack of specific information about the treatment of asthma in smokers. The asthmatic smoker
      is a special phenotype with important therapeutic and prognostic clinical implications.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>airway corticosteroid sensitivity</measure>
    <time_frame>two weeks</time_frame>
    <description>Airway corticosteroid sensitivity will be assessed by change in pre-bronchodilator FEV1 (forced expiratory volume at one second) to a two week trial of drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>one day</time_frame>
    <description>pre- and post bronchodilator FEV1 will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum cytology</measure>
    <time_frame>one day</time_frame>
    <description>detect proportion of eosinophils and neutrophils in sputum cytology.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Bronchial Asthma</condition>
  <arm_group>
    <arm_group_label>smoker asthmatics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asthma control questionnaire (ACQ) score
Spirometry
Sputum cytology
Airway corticosteroid sensitivity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-smoker asthmatics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asthma control questionnaire (ACQ) score
Spirometry
Sputum cytology
Airway corticosteroid sensitivity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>Airway corticosteroid sensitivity will be assessed by change in pre-brochodilator FEV1 to two week trial of drug.</description>
    <arm_group_label>smoker asthmatics</arm_group_label>
    <arm_group_label>non-smoker asthmatics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All asthmatic patients (however smokers ,or non-smokers) will be included.

        Exclusion Criteria:

          -  Acute severe asthma.

          -  Causes of airway obstruction other than asthma as COPD patients, bronchiectasis,
             ...etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Atef F Al-karn, MD</last_name>
    <phone>01006474200</phone>
    <email>afaroukeg@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed F Abd El-Ghany, MD</last_name>
    <phone>01006800525</phone>
    <email>mfawzy2013@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assuit University Hospital</name>
      <address>
        <city>Assiut</city>
        <zip>Assiut university 71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Vozoris NT, Stanbrook MB. Smoking prevalence, behaviours, and cessation among individuals with COPD or asthma. Respir Med. 2011 Mar;105(3):477-84. doi: 10.1016/j.rmed.2010.08.011. Epub 2010 Sep 17.</citation>
    <PMID>20850288</PMID>
  </reference>
  <reference>
    <citation>Cerveri I, Cazzoletti L, Corsico AG, Marcon A, Niniano R, Grosso A, Ronzoni V, Accordini S, Janson C, Pin I, Siroux V, de Marco R. The impact of cigarette smoking on asthma: a population-based international cohort study. Int Arch Allergy Immunol. 2012;158(2):175-83. doi: 10.1159/000330900. Epub 2012 Jan 26.</citation>
    <PMID>22286571</PMID>
  </reference>
  <reference>
    <citation>Chaudhuri R, McSharry C, McCoard A, Livingston E, Hothersall E, Spears M, Lafferty J, Thomson NC. Role of symptoms and lung function in determining asthma control in smokers with asthma. Allergy. 2008 Jan;63(1):132-5.</citation>
    <PMID>18053022</PMID>
  </reference>
  <reference>
    <citation>Clatworthy J, Price D, Ryan D, Haughney J, Horne R. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J. 2009 Dec;18(4):300-5. doi: 10.4104/pcrj.2009.00037.</citation>
    <PMID>19562233</PMID>
  </reference>
  <reference>
    <citation>Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002 Mar;57(3):226-30.</citation>
    <PMID>11867826</PMID>
  </reference>
  <reference>
    <citation>Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, Deykin A, DiMango E, Fish JE, Ford JG, Israel E, Kiley J, Kraft M, Lemanske RF Jr, Leone FT, Martin RJ, Pesola GR, Peters SP, Sorkness CA, Szefler SJ, Wechsler ME, Fahy JV; National Heart Lung and Blood Institute's Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007 Apr 15;175(8):783-90. Epub 2007 Jan 4.</citation>
    <PMID>17204725</PMID>
  </reference>
  <reference>
    <citation>James AL, Palmer LJ, Kicic E, Maxwell PS, Lagan SE, Ryan GF, Musk AW. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005 Jan 15;171(2):109-14. Epub 2004 Oct 14.</citation>
    <PMID>15486340</PMID>
  </reference>
  <reference>
    <citation>Lange P, Scharling H, Ulrik CS, Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax. 2006 Feb;61(2):100-4.</citation>
    <PMID>16443705</PMID>
  </reference>
  <reference>
    <citation>O'Byrne PM, Lamm CJ, Busse WW, Tan WC, Pedersen S; START Investigators Group. The effects of inhaled budesonide on lung function in smokers and nonsmokers with mild persistent asthma. Chest. 2009 Dec;136(6):1514-1520. doi: 10.1378/chest.09-1049. Epub 2009 Aug 26.</citation>
    <PMID>19710291</PMID>
  </reference>
  <reference>
    <citation>Tamimi A, Serdarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med. 2012 Mar;106(3):319-28. doi: 10.1016/j.rmed.2011.11.003. Epub 2011 Dec 22. Review.</citation>
    <PMID>22196881</PMID>
  </reference>
  <reference>
    <citation>Chatkin JM, Dullius CR. The management of asthmatic smokers. Asthma Res Pract. 2016 Jun 20;2:10. eCollection 2016. Review.</citation>
    <PMID>27965778</PMID>
  </reference>
  <reference>
    <citation>Hiroshima K, Iyoda A, Shibuya K, Hoshino H, Haga Y, Toyozaki T, Shiba M, Baba M, Fujisawa T, Ohwada H. Evidence of neoangiogenesis and an increase in the number of proliferating cells within the bronchial epithelium of smokers. Cancer. 2002 Oct 1;95(7):1539-45.</citation>
    <PMID>12237923</PMID>
  </reference>
  <reference>
    <citation>Mathé G, Santelli G, Gouveia J, Lemaigre G, Misset JL, Gros F, Homasson JP, Kim B, Sudre MC, Gaget H. Correlation of bronchial epidermoid metaplasia with level of tobacco consumption in heavy smokers. Cancer Detect Prev. 1986;9(1-2):79-81.</citation>
    <PMID>3731197</PMID>
  </reference>
  <reference>
    <citation>Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med. 1974 Oct 10;291(15):755-8.</citation>
    <PMID>4414996</PMID>
  </reference>
  <reference>
    <citation>Cosio MG, Hale KA, Niewoehner DE. Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis. 1980 Aug;122(2):265-21.</citation>
    <PMID>7416603</PMID>
  </reference>
  <reference>
    <citation>McSharry C, Spears M, Chaudhuri R, Cameron EJ, Husi H, Thomson NC. Increased sputum endotoxin levels are associated with an impaired lung function response to oral steroids in asthmatic patients. J Allergy Clin Immunol. 2014 Nov;134(5):1068-75. doi: 10.1016/j.jaci.2014.08.022. Epub 2014 Sep 26.</citation>
    <PMID>25262463</PMID>
  </reference>
  <reference>
    <citation>Decramer M, Louis R, Joos G, De Vuyst P, Mast B, Mehuys A; Pulmonary Advisory Board. (Ex-)smoking asthma patients in general and specialized Belgian practice. Respir Med. 2011 Aug;105(8):1203-10. doi: 10.1016/j.rmed.2011.02.017. Epub 2011 Mar 16.</citation>
    <PMID>21414762</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Safaa Abd El-gayed Eid</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

